Thrivent Financial for Lutherans’s Novavax NVAX Stock Holding History

Thrivent Financial for Lutherans’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$510K	Sell	62,642 -13,945	-18%	-$126K	﹤0.01%	2212
2025 Q4	$515K	Buy	+76,587	New	+$577K	﹤0.01%	2247
2025 Q3	–	Sell	-209,641	Closed	-$1.32M	–	2539
2025 Q2	$1.32M	Buy	+209,641	New	+$1.39M	﹤0.01%	1613
2021 Q2	–	Sell	-37,494	Closed	-$6.8M	–	2504
2021 Q1	$6.8M	Buy	+37,494	New	+$7.47M	0.02%	793
2015 Q1	–	Sell	-13,218	Closed	-$1.57M	–	1842
2014 Q4	$1.57M	Sell	13,218 -905	-6%	-$94.6K	0.01%	744
2014 Q3	$1.18M	Buy	+14,123	New	+$1.28M	0.01%	824

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Thrivent Financial for Lutherans's NVAX Position: Q1 2026 in Review

Thrivent Financial for Lutherans reduced its Novavax (NVAX) stake by 18% in Q1 2026, selling an estimated $126K and leaving 62,642 shares worth $510K. The position accounts for ﹤0.01% of the portfolio, ranked #2212.

Thrivent Financial for Lutherans first reported a position in NVAX in Q3 2014 and has held it in 6 quarters since. The position peaked at $6.8M in Q1 2021. 258 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

Thrivent Financial for Lutherans held 62,642 shares of Novavax worth $510K as of Q1 2026.
Thrivent Financial for Lutherans sold 13,945 Novavax shares in Q1 2026, an estimated $126K.
Novavax made up ﹤0.01% of Thrivent Financial for Lutherans's portfolio in Q1 2026, its #2212 holding.
Thrivent Financial for Lutherans first reported a position in Novavax in Q3 2014 and has held it in 6 quarters since.
Thrivent Financial for Lutherans's Novavax position peaked at $6.8M in Q1 2021.
258 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2026, filed 1 May 2026.